CME for IKCS 2020 is jointly provided by The France Foundation and the Kidney Cancer Association.

Need Your IKCS 2020 CME Credits?

Start with the evaluation form here: https://survey.alchemer.com/s3/5977606/IKCS-2020

Target Audience

This educational activity is directed toward medical oncologists and urologists who treat patients with kidney cancer. Fellow, trainees, nurses, nurse practitioners, physician assistants, and other healthcare professionals involved in the management of kidney cancer are invited to participate.

Statement of Need

Education and interaction surrounding the space of renal cell carcinoma are paramount to improving patient care. This program is targeted to physicians, advocates and researchers to help promote learning and collaboration for advancement in the renal cancer space.

Educational Activity Learning Objectives

Upon completion of this course, the participants should be able to:

  1. Characterize the various therapies currently available for locally advanced and metastatic renal cell carcinoma (RCC)
  2. Identify the novel approaches to non-clear cell RCC trial design and patient management
  3. Understand the role of metabolism as both a driver in RCC pathogenesis and as a target in its treatment

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and the Kidney Cancer Association. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Physicians: The France Foundation designates this live virtual activity for a maximum of 8.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Ethics: This course has been designated for 1.5 credit(s) of education in medical ethics and/or professional responsibility.

Method of Participation/How to Receive Credit

  1. Review the activity objectives and CME/CE information.
  2. Participate in the CME/CE activity.
  3. Complete the CME/CE evaluation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  4. Credit/documentation reporting:
    1. If you are requesting AMA PRA Category 1 Credit(s)™ or a certificate of participation—your CME/CE certificate will be made available for download.
    2. If you are requesting medical ethics and/or professional responsibility credit, you will receive documentation that you can submit to your board. You will receive a link to the CME/CE evaluation form after the activity. 

Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and the Kidney Cancer Association (KCA) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and KCA resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and KCA seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and KCA are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Activity Staff Disclosures

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

The planners, reviewers, editors, staff, CME committee, or other members at the Kidney Cancer Association who control content have no relevant financial relationships to disclose.

Faculty Disclosures-Activity Faculty

The following faculty report that they have relevant financial relationships to disclose:

  • Dr. Alex Bex has consulted (non-CE) for Novartis, Ipsen, and Bristol Myers Squib
  • Dr. Arpita Desai has served as contract researcher for Merck and Genentech/Roche
  • Dr. Rana R. McKay has served on advisory boards for Bayer, Bristol Myers Squib, Exelixis, Inc., Janssen, Novartis, and Pfizer, Inc. She has received institutional research funding from Bayer, Pfizer, Inc., and Tempus.
  • Dr. Ivan Pedrosa has consulted (non-CE) for Bayer Healthcare. He has received future stock options from Health Tech International. Dr. Pedrosa has intellectual property rights/patent holder licensed from Philips Healthcare.
  • Dr. Sarah P. Psutka has served as contract researcher for Prime Education, Inc.
  • Dr. Brian Rini has consulted (non-CE) for Merck, Bristol Myers Squib, Pfizer, Inc., Arrowhead, Immunicom, and Allermed. He has received institutional contract research from Merck, Exelixis, Inc., Bristol Myers Squibb, and Roche
  • Dr. Elizabeth Wulff-Burchfield has consulted (non-CE) for Elelixis, Inc., and Astellas. She is a stockholder of Immunomedics and Nektar Therapeutics.
  • Dr. Abhishek Tripathi has consulted (non-CE) for Pfizer, Inc., and Foundation Medicine. He serves as contract researcher for WindMil Therapeutics, Aravive, Inc., EMD Serono, Bayer, and Corvus Pharmaceuticals.
  • Dr. David Braun has consulted (non-CE) for LM Education and Exchange Services and Schlesinger Advisors.
  • Dr. William C. Huang has served on speakers bureau (non-CE) for Intuitive Surgical. He served as contract researcher for Urogen.
  • Dr. Viktor Grünwald has consulted (non-CE) for BMS, MSD, Ipsen, Eusa, Eisai, Pfizer, Inc., Novartis, AstraZeneca, and Merck. He has served on speakers bureaus (non-CE) for Bristol Myers Squibb, MSD, Merck, Ipsen, and Pfizer, Inc. Dr. Grünwald has served as research contractor for BMS, MSD, and Ipsen.
  • Dr. Raj Gupta has consulted (non-CE) for Bayer Pharma AG, Invivo Corporation, and Bard. He has served on speakers bureau (non-CE) for Bayer Pharma AG.
  • Dr. Rahul Sheth has consulted (non-CE) for Medtronic, Varian, and Boston Scientific.
  • Dr. Nizar Tannir has consulted (non-CE) for Bristol Myers Squibb; Pfizer, Inc., Nektar Therapeutics; Exelisis, Inc, Eisai Medical Research; Eli Lilly; Oncorena; Ono Pharmaceutical; Calithera Bioscience; Surface Oncology; Novartis, and Ipsen. He has served as contract researcher for Bristol-Myers-Squibb; Pfizer; Inc., Nektar Therapeutics; Exelixis, Inc, Calithera Bioscience; Mirati Therapeutics; and Epizyme Inc.
  • Dr. Masatoshi Eto has served on speakers bureaus (non-CE) for ONO, Takeda, Novartis, Pfizer, BMS, and Janssen. He has served as contract researcher for Sanofi, Bayer, Astellas, ONO, and Takeda.
  • Dr. Laurence Albiges has consulted (non-CE) for AstraZeneca, Novartis, MSD, Exelixis, Inc., Pfizer, Bristol Myers Squibb, Ipsen, Corvus Pharmaceuticals, Merck, Astellas, and Janssen.
  • Dr. Pavlos Msaoel has consulted (non-CE) for Bristol Myers Squibb, Exelixis, Inc., and Mirati Therapeutics.
  • Dr. Brad McGregor has consulted (non-CE) for Pfizer, Dendreon, Exelixis, Inc., Seattle Genetics, Asetllas, Bristol Myers Squibb, and Eisai. He has served as contract researcher for Seattle Genetics, Bristol Myers Squibb, Exelixis, Inc., and Calithera.
  • Dr. Eric Singer has served as contract researcher for Astellas and Medivation.
  • Dr. Christopher Wood has consulted (non-CE) and served on speakers bureaus (non-CE) for Pfizer, Inc., and Merck. He has served as contract researcher for Mirati and CoImmune.
  • Dr. Chung-Han Lee has consulted (non-CE) for Amgen, Bristol Myers Squibb, Exelixis, Inc., Eisai, Merck, Pfizer, Inc., and EMD Serono. He has served as contract researcher for Bristol Myers Squibb, Calithera, Eisai, Eli Lilly, Exelixis, Inc., Merck, and Pfizer, Inc.
  • Dr. Matthew T. Campbell has consulted (non-CE) for Eisai, Exelixis, Inc., EMD Serono, Pfizer, Inc., AstraZeneca, and Seattle Genetics. He has served as contract researcher for Exelixis, Inc., EMD Serono, Pfizer, Inc., and Apricity Health.
  • Laura Wood has consulted (non-CE) for Eisai. She has served on speakers bureaus (non-CE) for Bristol Myers Squibb, Merck, and Pfizer, Inc.
  • Dr. Tian Zhang has consulted (non-CE) for AstraZeneca, Pfizer, Inc., Foundation Medicine, MJH Associates, IQVIA, and Pacific Genuity. Her spouse is employed by and is a stockholder of Capio Biosciences and Archimmune Therapeutics. He is also a stockholder and has served as consultant (non-CE) for Nanorobotics.
  • Dr. Ulka Vaishampayan has consulted (non-CE) for Bristol Myers Squibb, Exelixis, Inc., Merck, and Pfizer, Inc. She has served on speakers bureaus (non-CE) for Bristol Myers Squibb, Exelixis, Inc., and Pfizer, Inc. Dr. Vaishampayan has served as contract researcher for Bristol Myers Squibb and Astellas.
  • Dr. Brian Shuch has consulted (non-CE) for Calithera. He has served as contract researcher for NIH, SWOG, and Hope Foundation. Dr. Shuch has received royalties from UpToDate, Inc.
  • Dr. Thomas Powles has consulted (non-CE) for AstraZeneca, Bristol Myers Squibb, Exelixis, Inc., Incyte, Ipsen, Merck, MSD, Novartis, Pfizer, Inc., Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, and Eisai. He has served as contract researcher for AstraZeneca, Bristol Myers Squibb, Exelixis, Inc., Ipsen, Merck, MSD, Novartis, Pfizer, Inc., Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, and Eisai.
  • Dr. William G. Kaelin, Jr. has consulted (non-CE) for Lilly Pharmaceuticals, Duke University,  Agios Pharmaceuticals, Circle Pharma, FibroGen, Nextech Invest, TRACON Pharmaceuticals, Cedilla Therapeutics, and Tango Therapeutics. He has served as contract researcher for HHMI, NIH/NCI, and BCRF. Dr. Kaelin is a stockholder of Lilly Pharmaceuticals, Agios Pharmaceuticals, Cedilla Therapeutics, Circle Pharma, FibroGen, Infinity Pharmaceuticals, and. Tango Therapeutics. He has received future stock options of Agios Therapeutics, and TRACON Pharmaceuticals. Dr. Kaelin holds intellectual property rights/patent holder licensed from FibroGen, Inc. and receives royalties from FibroGen, Inc., and Peloton/Merck. He has carried interest in Nextech Invest.
  • Dr. Eric Jonasch has consulted (non-CE) for Aveo, Eisai, Exelixis, Inc., Merck, Novartis, and Pfizer, Inc. He has served as contract researcher for Merck.
  • Dr. Thomas E. Hutson has consulted (non-CE) for Pfizer, Inc., and EMD Serono. He has served on speakers bureaus (non-CE) for Exelixis, Inc., and Astellas. Dr. Hutson has served as contract researcher for Merck, AstraZeneca, and Janssen.
  • Dr. Naomi Balzer Haas has consulted (non-CE) for Calithera and Eisai.
  • Dr. Shuchi Gulati has served as contract researcher for Astrazeneca and Isoray.
  • Dr. André Fay has consulted (non-CE) for Bristol Myers Squibb, MSD, Roche, AstraZeneca, Pfizer, Inc., and Ipsen. He has served as contract researcher for Bristol Myers Squibb, MSD, Roche, and AstraZeneca.
  • Dr. Guillermo de Velasco has consulted (non-CE) for Pfizer, Inc., Merck, MSD, and Bristol Myers Squibb. He has served on speakers bureaus (non-CE) for Ipsen, Astellas, Roche, Bristol Myers Squibb, and Pfizer, Inc. Dr. de Velasco has served as contract researcher for Roche, Ipsen, and Pfizer, Inc.
  • Dr. Timothy Chan has consulted (non-CE) for Bristol Myers Squibb, Illumina, and Astrazeneca. He is stockholder, advisory board member, and has received future stock options from Gritstone and Nysno Bio. Dr. Chan has received royalties from PGDX.
  • Dr. Johanna Bendell has consulted (non-CE) for Gilead, Genentech/Roche, Bristol Myers Squibb, Five Prime, Lilly, Merck, MedImmune, Celgene, Taiho, Macrogenics, GlaxoSmithKline, Novartis, OncoMed, LEAP, TG Therapeutics, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Bayer, Incyte , Apexigen, Array, Sanofi, ARMO, Ipsen, Merrimack, Oncogenex, FORMA, Arch Oncology, Prelude Therapeutics, Phoenix Bio, Cyteir, Molecular Partners, Innate, Torque, Tizona. Janssen, Tolero, TD2 (Translational Drug Development), Amgen, Seattle Genetics, Moderna Therapeutics, Tanabe Research Laboratories, Beigene, Continuum Clinical, Agios, Bicycle Therapeutics, Relay Therapeutics, Evelo, Pfizer, Inc., Piper Biotech, Samsung Bioepios, and Fusion Therapeutics. She has received institutional research funding from Gilead, Genentech/Roche, Bristol Myers Squibb, Five Prime, Lilly, Merck, MedImmune, Celgene, EMD Serono,Taiho, Macrogenics, GlaxoSmithKline, Novartis, OncoMed, LEAP, TG Therapeutics, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Bayer, Incyte, Apexigen, Koltan, SynDevRex, Forty Seven, AbbVie, Array, Onyx, Sanofi, Takeda , Eisai, Celldex, Agios, Cytomx, Nektar, ARMO, Boston Biomedical, Ipsen, Merrimack, Tarveda, Tyrogenex, Oncogenex, Marshall Edwards, Pieris, Mersana, Calithera, Blueprint, Evelo, FORMA, Merus, Jacobio, Effector, Novocare, Arrys, Tracon, Sierra, Innate, Arch Oncology, Prelude Oncology, Unum Therapeutics, Vyriad, Harpoon, ADC, Amgen, Pfizer, Inc., Millennium, Imclone, Acerta Pharma, Rgenix, Bellicum, Gossamer Bio, Arcus Bio, Seattle Genetics, TempestTx, Shattuck Labs, Synthorx, Inc., Revolution Medicines, Inc., Bicycle Therapeutics, Zymeworks, Relay Therapeutics, Scholar Rock, NGM Biopharma, Stemcentrx, Beigene, CALGB, Cyteir Therapeutics, Foundation Bio, Innate Pharma, Morphotex, Ongologie, NuMab, AtlasMedx, Treadwell Therapeutics, IGM Biosciences, Mabspace, Hutchinson MediPharma, REPARE Therapeutics, and NeoImmune Tech.
  • Dr. Katy Beckerman has consulted (non-CE) for Aravive, Exelixis, Inc., and OncLive. She has served as contract researcher for Bristol Myers Squibb.
  • Dr. Darren Feldman has served as contract researcher for Novartis, Astellas, and Decibel Therapeutics. He receives royalty from UpToDate, Inc.
  • Dr. Martin Voss has consulted (non-CE) for Eisai, Exelixis, Inc., and Merck. He has served as contract researcher for Pfizer and Bristol Myers Squibb.
  • Dr. Charles Drake has consulted (non-CE) for Bayer, Bristol Myers Squibb, Compugen, F-Star, Genocea, Janssen, Kleo, Merck, Merck-Serono, Pfizer, Inc., Pierre Fabre, Roche / Genentech, Shattuck Labs, Tizona, and Werewolf Pharmaceuticals. He is a stockholder of Compugen, Harpoon, UroGen, and Werewolf Pharmaceuticals. Dr. Drake has intellectual property rights/patent holder licensed from Johns Hopkins University and Bristol Myers Squibb. He has recently accepted staff position at Janssen Research and Development.

The faculty listed below report they have no relevant financial relationships to disclose:

  • Dr. Steven C. Campbell
  • Dr. Maria I. Carlo
  • Dr. Hyung Kim
  • Dr. Vitaly Margulis
  • Dr. Aikseng Ooi
  • Dr. Tracy L. Rose
  • Dr. Lucas A. Salas
  • Dr. Brian Shinder
  • Dr. Abhishek A. Chakraborty
  • Dr. Deborah R. Kaye
  • Dr. Eduard Reznik
  • Dr. Gopal Gupta
  • Dr. Laura Banaszynski
  • Dr. Vladimir Kolenko
  • Dr. Stephanie Berg
  • Dr. Suzanne Cole
  • Dr. Mark W. Ball
  • Dr. Matthew D. Tucker
  • Dr. Yue Zhao
  • Dr. Eric Kauffman
  • Dr. Jack Gleeson
  • Dr. Alex Chehrazi-Raffle
  • Dr. E. Jason Abel
  • Dr. Paul Russo
  • Dr. Arnav Srivastava
  • Dr. Luis Andres Meza Contreras
  • Dr. Adam Metwalli
  • Megan Conley
  • Dr. Sumanta Pal

Disclosure of Unlabeled Use

TFF and KCA require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and KCA do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Disclaimer

The France Foundation and the Kidney Cancer Association present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, the Kidney Cancer Association, and the commercial supporter assume no liability for the information herein.